![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ACH-3422, a Novel Nucleotide Prodrug Inhibitor of HCV NS5B Polymerase
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Frank Weilert5, Katherine Stuart6, Wendy Cheng7, Joanna Yang8, Heather Robison8, James Hui8, John Lahey8, Robert Sorensen8, David Apelian8, Robert Hindes8
Affiliations: 1Auckland Clinical Studies Ltd, Grafton, New Zealand; 2Auckland City Hospital, Auckland, New Zealand; 3Christchurch Clinical Studies Trust and 4Christchurch Hospital, Christchurch, New Zealand; 5Waikato Hospital and Waikato District health Board, Hamilton, New Zealand; 6Q-Pharm Pty Ltd and Gallipoli Medical Research Foundation, Brisbane, Australia; 7Linear Clinical Research and Royal Perth Hospital, Perth, Australia; 8Achillion Pharmaceuticals, New Haven, CT, USA
![EASL1.gif](../images/043115/043115-6/EASL1.gif)
![EASL2.gif](../images/043115/043115-6/EASL2.gif)
![EASL3.gif](../images/043115/043115-6/EASL3.gif)
![EASL4.gif](../images/043115/043115-6/EASL4.gif)
![EASL5.gif](../images/043115/043115-6/EASL5.gif)
![EASL6.gif](../images/043115/043115-6/EASL6.gif)
![EASL7.gif](../images/043115/043115-6/EASL7.gif)
![EASL8.gif](../images/043115/043115-6/EASL8.gif)
![EASL9.gif](../images/043115/043115-6/EASL9.gif)
![EASL10.gif](../images/043115/043115-6/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|